Announcement PDF NASDAQ: IMRN ASX: IMC FY25 Results Presentation Steven Lydeamore Chief Executive Officer 29 August 2025 SAFE HARBOR STATEMENT C e r t a i n s t a t e m e nt s m a d e i n t h i s p re s e nt a t i o n a re fo r wa rd - l o o k i n g s t a t e m e nt s a n d a re b a s e d o n I m m u ro n ’s c u r re nt ex p e c t a t i o n s , e s t i m a t e s a n d p ro j e c t i o n s . Wo rd s s u c h a s “a nt i c i p a t e s ,” “ex p e c t s ,” “ i nt e n d s ,” “ p l a n s ,” “ b e l i e v e s ,” “s e e k s ,” “e s t i m at e s ,” “g u i d a n c e ” a n d s i m i l a r ex p re s s i o n s a re i nt e n d e d t o i d e nt i f y fo r wa rd - l o ok i n g s t a t e m e nt s . A l t h o u g h I m m u ro n b e l i e v e s t h e fo r wa rd - l o o k i n g s t a t e m e nt s a re b a s e d o n re a s o n a b l e a s s u m p t i o n s , t h e y a re s u b j e c t t o c e r t a i n r i s k s a n d u n c e r t a i nt i e s , s o m e o f w h i c h a re b e y o n d I m m u ro n ’s co nt ro l , i n c l u d i n g t h o s e r i s k s o r u n c e r t a i nt i e s i n h e re nt i n t h e p ro c e s s o f b o t h d e v e l o p i n g a n d co m m e rc i a l i z i n g t e c h n o l o g y. A s a re s u l t , a c t u a l re s u l t s co u l d m a t e r i a l l y d i f fe r f ro m t h o s e ex p re s s e d o r fo re ca st e d i n t h e fo r wa rd - l o o k i n g s t a t e m e nt s . T h e fo r wa rd - l o ok i n g s t a t e m e nt s m a d e i n t h i s p re s e nt a t i o n re l a t e o n l y t o e v e nt s a s o f t h e d a t e o n w h i c h t h e s t a t e m e nt s a re m a d e . I m m u ro n w i l l n o t u n d e r t a ke a ny o b l i ga t i o n t o re l e a s e p u b l i c l y a ny re v i s i o n s o r u p d a t e s t o t h e s e fo r wa rd- l o o k i n g s t a t e m e nt s t o re f l e c t e v e nt s , c i rc u m sta n c e s o r u n a nt i c i p a t e d e v e nt s o c c u r r i n g a f t e r t h e d a t e o f t h i s p re s e nt a t i o n exc e p t a s re q u i re d by l a w o r by a ny a p p ro p r i at e re g u l a t o r y a u t h o r i t y. F Y 2 0 2 5 re s u l t s i n t h i s p re s e nt a t i o n a re s u b j e c t t o a u d i t re v i e w. Executive summary Immuron Ltd (NASDAQ:IMRN) (ASX:IMC) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases Company Overview Financial Snapshot Three commercial products: Travelan® (traveller’s diarrhoea), Protectyn® and ProIBS (irritable bowel syndrome) Three clinical programs: Travelan®: IMC: Phase 2 CHIM trial (n=60) Shares on Issue 268,219,973 Travelan®: USU: Field Study (n=866) Total Options 13,540,315 IMM-529 (CDI): IMC: preparing IND for Phase 2 trial (n=60) Last Traded Price IMC: A$0.068 52 week High/Low IMC: A$0.11/0.054 IMRN: $2.87/1.50 Market Cap IMC: A$18.23m Cash & Term Deposit (30 June 2025) – Excludes A$2.8m raised from US placement (July 2025) A$5.9m Business Update Clinical: Commercial: Travelan® (IMM-124E) Travelan® Uniformed Services University IMM-124E trial 100% of 866 participants have been randomized and deployed Continued quarter on quarter growth of Travelan® Travelan® (IMM-124E) Travelan® Uniformed Services University IMM-124E trial topline results anticipated in October 2025 ProIBS launch stock ordered IMM-529 (CDI): Immuron anticipates submission of Investigational New Drug (IND) by end of September 2025 Major Shareholders IMM-986 (VRE): Colostrum manufactured for preclinical studies; assay development in progress Results, Upcoming Milestones & Outlook FY25 Results: FY25 Global Sales Revenue of A$7.3 million up 49% on prior year – North American Travelan® sales A$2.0 million up 76% on prior year Profit1 from Hyperimmune products for FY25 was A$1.35m, the same as FY24; FY25 increased selling & marketing investment A$1.4m 1 Segment reporting; excludes Research & Development and Corporate segments. Continued quarter on quarter growth of Travelan® from growth drivers Australian launch of ProIBS 1Q CY2026 Clinical Development Travelan® IMM-124E: 1H 2026: End of Phase 2 FDA meeting (Phase 2; n=60) IMM-529 (CDI): Immuron anticipates FDA approval of IND in December 2025 Units % of CSO BNY Mellon Asset Management 113,417,824 42.29 % Authentics Australia Pty. Ltd. 5,500,000 2.05 % Grandlodge 3,846,712 1.43 % Management & Board 3,234,153 1.21 % Holder 3 1. FINANCIAL & OPERATIONAL HIGHLIGHTS FY25 Financial Summary Global Sales Revenue $7.3m Up 49% Australian Sales Revenue $5.3m Up 40% North American Sales Revenue $2.0m Up 76% Gross Profit Margin 65.4% EBITDA (ex-R&D)1 $(3.1)m $2.1m improvement Cash + Term Deposit $5.9m (excludes A$2.8m raised from the US placement)2 1 ex-R&D: add back research & development, less R&D Tax Incentive and R&D grants; 2 30 June 2025, as reported in Immuron’s Appendix 4E (Cash $2.83m; Term Deposit $3.04m) and excludes the A$2.8m raised from the US placement of 32.9m shares at the AUD equivalent of $0.0824 per share conducted on the Nasdaq:IMRN completed 17 July 2025. The shares were purchased by US investors from Immuron’s US At-The-Market (ATM) facility. The ATM facility has now been fully utilised. 5 Travelan® continued strong sales growth Global Year to Date Net Sales ($AUD) Global + FY2025 AUD$7.3 million up 49% on prior year $8,000,000 $7,000,000 $6,000,000 $5,000,000 $4,000,000 $3,000,000 $2,000,000 $1,000,000 $- Australia Jul - Sep Oct - Dec FY24 Jan - Mar Apr - Jun FY25 + FY2025 AUD$5.2 million up 40% on prior year + Secured core ranging in additional nine pharmacy banner groups North America + FY2025 AUD$2.0 million up 76% on prior year + Strongest sales growth on amazon.com + Secured distribution in ten pharmacy/grocery retailers in Canada 6 Commercial – Operational Highlights 2H FY24 1H FY24 2H FY25 and Outlook 1H FY25 Travelan® / Protectyn® Revenue • • • $2.36m global sales $1.87m Australia $0.48m North America • • • • • • $2.55m global sales $1.87m Australia $0.67m North America $4.00m global sales $2.89m Australia $1.11m North America Marketing & Distribution • • • $3.29m global sales $2.36m Australia $0.93m North America • Australia: 3,700 pharmacies; 27m people Canada: 10,000 pharmacies; 39m people USA: 342m people • • ProIBS Highlights • Exclusive distribution of ProIBS® for the treatment of symptoms related to IBS in Australia and New Zealand. • Purchase order placed with anticipated delivery in 3Q2025. Anticipated product launch in 1Q CY2026. 7 2. CLINICAL DEVELOPMENT PROGRAM Revenue generating with a strong clinical development pipeline Indication Traveller’s Diarrhoea Clostridioides Difficile Vancomycin Resistant Enterococci 30 August 2024 29 August 2025 Travelan® (IMM-124E) Phase 2 Clinical study topline data reported in March 2024 Clinical study report submitted to FDA in January 2025 Awaiting Travelan® Uniformed Services University clinical trial topline results (anticipated October 2025) before requesting end of Phase 2 meeting Travelan® Uniformed Services University clinical trial reaches 77% recruitment of 866 patients Travelan® Uniformed Services University clinical trial 100% of participants have been randomized and deployed Quality review of study data initiated October 2025 anticipated top line results IMM-529 pre-IND submission to the FDA in July 2024 Planning IMM-529 FDA IND submission by end of September 2025 Anticipated IMM-529 FDA approval December 2025 New project (IMM-986) initiation of pre-clinical research collaboration with Monash University targeting Vancomycin Resistant Enterococci (VRE) Colostrum manufactured for preclinical studies. In Vitro method development initiated. 9 Status of product portfolio and key milestones Indication Traveller's Diarrhoea Compound Travelan® Peak U.S. sales US$ 102 m Preclinical Phase 1 Phase 2 Phase 3 Registration Collaborator or Funding Source Uniformed Services University Current Status 100% of 866 participants recruited Anticipated Dates 1H 2026 2H 2025 Topline Data End of Phase 2 FDA meeting IMM-124E Completed Clostridioides Difficile IMM-529 Pre-IND IND submission to submission to FDA FDA Vancomycin Resistant Enterococci IMM-986 US$ 400 m Manufacturing completed Preclinical activities 10 IND FDA approval (31 December 2025) In Vitro and In Vivo Preclinical data 3. UPCOMING MILESTONES & OUTLOOK Upcoming Milestones & Outlook Commercial + Continued quarter on quarter growth of Travelan® from growth drivers + Australian launch of ProIBS in Q1 CY2026 + Planned growth in profitability1 of Hyperimmune products net of planned increased investment in selling & marketing Clinical IMM-124E (Travelan®): Traveller’s Diarrhoea + IMM-124E: completed 100% recruitment, randomization and deployment (Phase 4; n=866) + IMM-124E: October 2025: Topline data (Phase 4; n=866) + IMM-124E: 1H 2026: End of Phase 2 FDA meeting (Phase 2; n=60) IMM-529: Clostridioides difficile infection (C.diff, CDI) + IMM-529: 30 September: FDA IND Submission + IMM-529: 31 December: FDA IND Approval 1 Segment reporting; excludes Research & Development and Corporate segments. 12 STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION: EMAIL: STEVE@IMMURON.COM PHONE: AUSTRALIA: +61 438 027 172